Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Non-Current Assets (2016 - 2026)

Champions Oncology (CSBR) has 15 years of Non-Current Assets data on record, last reported at $8.8 million in Q4 2025.

  • For Q4 2025, Non-Current Assets fell 20.85% year-over-year to $8.8 million; the TTM value through Oct 2025 reached $39.3 million, down 19.83%, while the annual FY2025 figure was $10.0 million, 20.07% down from the prior year.
  • Non-Current Assets reached $8.8 million in Q4 2025 per CSBR's latest filing, down from $9.5 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $16.0 million in Q3 2022 and bottomed at $8.8 million in Q4 2025.
  • Average Non-Current Assets over 5 years is $13.4 million, with a median of $14.6 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: surged 225.69% in 2021, then decreased 21.86% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $15.6 million in 2021, then increased by 1.04% to $15.8 million in 2022, then decreased by 9.39% to $14.3 million in 2023, then decreased by 21.86% to $11.2 million in 2024, then dropped by 20.85% to $8.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $8.8 million in Q4 2025, $9.5 million in Q3 2025, and $10.0 million in Q2 2025.